Frequent antibody production against RARα in both APL mice and patients

In an acute promyelocytic leukemia (APL)–transplantable mouse model, we previously reported the presence of antibodies recognizing PML-RARα and RARα in the sera of ATRA-treated mice. To evaluate this immune response, we determined the prevalence of anti-RARα antibodies in a cohort of 48 APL mice, treated by ATRA (n = 24) or by placebo pellets (n = 24), and in a preliminary subset of 9 patients with APL using a specific enzyme-linked immunosorbent assay (ELISA). In APL mice, significantly higher antibody levels were observed at the latest time points (day 48 to 58 levels superior to day 15 to 18 or day 28 to 38 levels). Antibody levels were higher in ATRA-treated mice than in placebo-treated mice and were also predictive of better survival. In the patients with APL, anti-RARα antibodies were detected at diagnosis and after maintenance therapy, reminiscent of the ATRA-treated APL mice. Antinuclear or antineutrophil cytoplasmic autoantibodies were also detected. These data reveal for the first time that in patients with APL an immune response may be detected at diagnosis and enhanced after maintenance therapy.

[1]  Federica Cavallo,et al.  Vaccines for tumour prevention , 2006, Nature Reviews Cancer.

[2]  Wei Xu,et al.  All-trans retinoic acid biases immune response induced by DNA vaccine in a Th2 direction. , 2005, Vaccine.

[3]  M. Robin,et al.  Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans , 2005, Cancer Immunology, Immunotherapy.

[4]  M. Robin,et al.  PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia , 2003, Nature Medicine.

[5]  P. Chambon,et al.  Retinoids Regulate Survival and Antigen Presentation by Immature Dendritic Cells , 2003, The Journal of experimental medicine.

[6]  J. Koziol,et al.  Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  M. Chiriva-Internati,et al.  Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. , 2003, Blood.

[8]  T. Ley,et al.  Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Saglio,et al.  Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. , 2001, Cancer research.

[10]  C. Stephensen.  Vitamin A, infection, and immune function. , 2001, Annual review of nutrition.

[11]  A. Gaiger,et al.  Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. , 2000, Blood.

[12]  W. Gianni,et al.  ErbB2 immune response in breast cancer patients with soluble receptor ectodomain. , 2000, The American journal of pathology.

[13]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[14]  J. Miguel,et al.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.

[15]  M. Davis,et al.  A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. , 1999, Cancer research.

[16]  Philip S. Livingston,et al.  Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21 , 1999, British Journal of Cancer.

[17]  P. Pfitzenmeyer,et al.  Prevalence of ANCA in a hospitalized elderly French population. , 1997, Clinical and experimental rheumatology.

[18]  J. Koziol,et al.  Range of antinuclear antibodies in "healthy" individuals. , 1997, Arthritis and rheumatism.

[19]  I. Weissman,et al.  A PMLRARα transgene initiates murine acute promyelocytic leukemia , 1997 .

[20]  I. Weissman,et al.  A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[22]  D. Byrd,et al.  Antibody to ras proteins in patients with colon cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  M. Cantorna,et al.  In vitamin A deficiency multiple mechanisms establish a regulatory T helper cell imbalance with excess Th1 and insufficient Th2 function. , 1994, Journal of immunology.

[24]  P. Chambon,et al.  Immunodetection of multiple species of retinoic acid receptor α : evidence for phosphorylation , 1992 .

[25]  A. Sommer,et al.  Depressed immune response to tetanus in children with vitamin A deficiency. , 1992, The Journal of nutrition.

[26]  P. Chambon,et al.  Immunodetection of multiple species of retinoic acid receptor alpha: evidence for phosphorylation. , 1992, Experimental cell research.

[27]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.